Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-13

Clinical Trial Update: Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

View source ↗

Summary

A completed prospective observational analysis evaluating complete remission in renal cell carcinoma patients treated with sunitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sunitinib (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Complete Remission in Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2023-11-13